2021-04-21 - Cancer Synoptic Reporting Project Group Meeting, Virtual Business Meeting

1

Conflict of Interest

@Scott Campbell

2

Concepts promoted to task and in queue for promotion

@Scott Campbell

1. Histologic type of neoplasm of X (64 new observable entities)

2. Histologic grade of neoplasm of X (81 concepts)

3. Anatomic locations invaded by neoplasm of X (90)

4. Perineural and Lymphovascular invasion (63)

5. Lymph node concepts (22)

6. Surgical margins involved by neoplasm of X (50)

7. Dimension concepts (50)

3

Concepts in review for inclusion in task

@Scott Campbell

1. Surgical margins (presence of involvement) moved to review (190+ concepts)

1. How to reflect margins that reference anatomical location 

2. JCA will allow editorial exception for anatomic structure in FSN of surgical margin when dictated by specific, limited cases defined by pathologists

4

Grade finding (finding)

@Suzanne Santamaria

Discuss clinical finding concepts in existing SI content.  To inactivate or not - Follow up with UK use case

1. Finding concepts not used in primary care.  Question outstanding for non-primary care use.

2. looks like we can deprecate the findings.  

5

Next concepts

@Scott Campbell

1. Tumor buds and tumor deposits

2. FIGO and other stage/grades?

3. Tumor focality

4. Treatment effect

5. Depth of invasion

6. Other areas

1. ENETS

2. FIGO

6

Business meeting

@Scott Campbell

I&E documents to do and review

Cancer Synoptic Reporting

7

Histology discussion

@Scott Campbell

Removal of 86049000 |Malignant neoplasm, primary (morphologic abnormality)| and similar high-level concepts.  Challenge for this group and disorders. 

Removal of concepts like: 2092003 |Malignant melanoma, no International Classification of Diseases for Oncology subtype (morphologic abnormality)|

1. How to model primary, metastatic and unknown processes in Observable entity concepts and in disorders
   
   

2. Impact on links to ICD-O-3 behavior codes
   
   

3. Impact on ICD-O-3 histology codes

Note:  primary/secondary/metastatic/unknown/post-treatment tumors discussion needs to move back to editorial advisory group.  FSN implications and definitions....more discussion needed.  

How does this impact grouper concepts